News By Tag
News By Location
Global Macular Degeneration (Amd) And Other Retinal Diseases Drugs Industry And Market 2018-2028
Age-related macular degeneration (AMD) and other retinal diseases market is growing rapidly in pharmaceutical industry worth multi-billion-
There are unmet needs remaining in retinal diseases sector and pharmaceutical companies are aiming to meet these needs within the next ten years. Companies seek to improve upon the standard of care (SOC) treatment for wAMD, whilst developing new therapies for dry AMD and other retinal diseases such as diabetic retinopathy (DR) and retinal vein occlusion (RVO). The retinal disease overall market is expected to keep growing for the next 10 years as current promising pipeline candidates attain approvals. The Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Other Retinal Diseases: World Drug Industry and Market Forecast 2018-2028 provides an analysis of this fast-growing market in 2018, as well as forecasting the prospects for revenue growth over the period 2018-2028.
In the second half of the forecast period, growth in the wet AMD segment will increasingly be driven by uptake of new products, including new combination regimens based on blocking of multiple pathways. However, the segment is mature relative to other retinal disease markets, and Visiongain (https://www.visiongain.com/)
That updated report shows revenue forecasts to 2028 at overall world market, disease submarket, product (brand) and national level. First it gives revenue predictions to 2028 for four therapeutic submarkets at world level:
· Wet age-related macular degeneration (wAMD)
· Dry AMD (dAMD)
· Diabetic retinopathy (DR)
· Other retinal diseases (grouped forecast).
That study then predicts revenues of four prominent drugs to 2028: Lucentis, Eylea, Avastin and Visudyne.
Research, data and analyses cover activities of Roche, Novartis, Bayer, Regeneron, Allergan, Valeant and other developers, manufacturers and marketers of ophthalmic pharmaceuticals. Analyses cover leaders and other organisations for retinal medicines.
That new study also discusses R&D and commercial news and predicts revenues to 2028 in 11 leading national markets. The work analyses the United States (US), Western Europe (Italy, Spain, Germany, the UK and France), Japan and BRIC countries (Brazil, Russia, India and China).
Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028 Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne adds to visiongain's (https://www.visiongain.com/)